Ivosidenib is an IDH1 inhibitor that has been approved for acute myeloid leukemia [79] and cholangiocarcinomas [80] and is being investigated in IDH-mutated gliomas [81], among other tumors. Here, IDH1 is linked to central nervous system cancer.